Dorian Hargrove 2:30 p.m., March 7
Neurocrine Zooms as Rest of Market Wilts
Stock of biotech Neurocrine Biosciences is up 37.36% this morning in an overall market slaughter. U.S. stock are down more than 2% this morning following big selloffs in Europe and Asia. Neurocrine said a mid-stage study of its drug to treat endometriosis, a gynecological condition, met main and secondary goals, according to Reuters. "In endometriosis, pieces of the uterine lining grow outside the womb, sometimes sticking to other organs," says Reuters. "The condition has no cure and can cause infertility." At one point, Neurocrine stock was up more than 50%.